• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Immunic Inc.

    4/9/26 4:30:55 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMUX alert in real time by email
    S-8 1 e665230_s8-immunic.htm

     

    As filed with the Securities and Exchange Commission on April 9, 2026

     

    Registration No. 333- 

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Immunic, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   56-2358443

    (State or Other Jurisdiction

    of Incorporation)

     

    (I.R.S. Employer

    Identification Number)

     

    1200 Avenue of the Americas, Suite 200

    New York, NY 10036

    (Address, including zip code, of registrant’s principal executive offices)

     

    Immunic, Inc. 2026 Inducement Plan 

    (Full title of the plan)

     

    Daniel Vitt

    Chief Executive Officer

    Immunic, Inc.

    1200 Avenue of the Americas, Suite 200

    New York, NY 10036

    (332) 255-9818

    (Name and address, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Ilan Katz, Esq.

    Grant Levine

    Dentons US LLP

    1221 Avenue of the Americas

    New York, New York 10020

    (212) 632-5556

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    On March 13, 2026, the Board of Directors of the Registrant (the “Board”) and the Compensation Committee of the Board (the “Committee”) adopted the Inducement Plan, effective as of March 13, 2026, pursuant to which the Registrant reserved 30,000,000 shares of common stock of the Registrant to be issued exclusively for grants of equity-based awards to individuals who were not previously employees or directors of the Registrant, as an inducement material to the individual’s entry into employment with the Registrant within the meaning of Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market (“Rule 5635(c)(4)”). The Inducement Plan provides for the grant of equity-based awards in the form of non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, and dividend equivalent rights. The Inducement Plan was adopted by the Board and the Committee without stockholder approval pursuant to Rule 5635(c)(4). This Registration Statement registers these 30,000,000 shares of common stock.

      


    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

     

    As permitted by Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants of the Registrant’s Inducement Plan as required by Rule 428(b) of the Securities Act.

     

    1 

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed with the Securities and Exchange Commission (the “SEC”) are hereby incorporated by reference in this registration statement:

     

    a.Our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with SEC on February 26, 2026;

     

    b.The Current Reports on Form 8-K filed with the SEC on January 5, 2026; January 6, 2026; February 13, 2026; February 26, 2026; March 31, 2026; and April 1, 2026; and

     

    c.The description of the registrant’s common stock contained in the registrant’s registration statement on Form 8-A, filed by the registrant with the SEC under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on November 13, 2013, including any amendments or reports filed for the purpose of updating such description.

     

    All documents filed after the date of this Registration Statement by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment that indicates that all shares of common stock offered hereunder have been sold or which deregisters all shares of common stock remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of the filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Under no circumstances will any information filed under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    We are incorporated under the laws of the state of Delaware. Section 145(a) of the Delaware General Corporation Law (the “DGCL”) provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

     

    2 

     

     

    Section 145(b) of the DGCL provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, joint venture, trust or other enterprise, against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper.

     

    Further subsections of DGCL Section 145 provide that:

     

    (1) to the extent a present or former director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a) and (b) of Section 145 or in the defense of any claim, issue or matter therein, such person shall be indemnified against expenses, including attorneys’ fees, actually and reasonably incurred by such person in connection therewith;

     

    (2) the indemnification and advancement of expenses provided for pursuant to Section 145 shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise; and

     

    (3) the corporation shall have the power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the corporation would have the power to indemnify such person against such liability under Section 145 of the DGCL.

     

    Section 145 of the DGCL makes provision for the indemnification of officers and directors in terms sufficiently broad to indemnify our officers and directors under certain circumstances from liabilities (including reimbursement for expenses incurred) arising under the Securities Act of 1933, as amended (the “Securities Act”). Our bylaws provide, in effect, that, to the fullest extent and under the circumstances permitted by Section 145 of the DGCL, we will indemnify any person (and the estate of any person) who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was a director or officer of our company or is or was serving at our request as a director or officer of another corporation or enterprise. We may, in our discretion, similarly indemnify its employees and agents.

     

    We have entered into indemnification agreements with our officers and directors.

     

    Our certificate of incorporation relieves our directors from monetary damages to us or our stockholders for breach of such director’s fiduciary duty as a director to the fullest extent permitted by the DGCL. Under Section 102(b)(7) of the DGCL, a corporation may relieve its directors from personal liability to such corporation or its stockholders for monetary damages for any breach of their fiduciary duty as directors except (i) for a breach of the duty of loyalty, (ii) for acts or omissions not in good faith, or which involve intentional misconduct or a knowing violation of law, (iii) for willful or negligent violations of certain provisions in the DGCL imposing certain requirements with respect to stock repurchases, redemptions and dividends, or (iv) for any transactions from which the director derived an improper personal benefit.

     

    3 

     

     

    We currently maintain an insurance policy which, within the limits and subject to the terms and conditions thereof, covers certain expenses and liabilities that may be incurred by directors and officers in connection with proceedings that may be brought against them as a result of an act or omission committed or suffered while acting as a director or officer of our company.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    See the Exhibit Index below for a list of exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed the value we registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of a prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; provided, however, that paragraphs (1)(i) and (1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement;

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    4 

     

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    INDEX TO EXHIBITS

     

    Exhibit     Incorporated by Reference
    Number Exhibit Description   Form   Exhibit   Filing Date
                   
    4.1 Amended and Restated Certificate of Incorporation.   8-K   3.1   July 19, 2019
                   
    4.2 Certificate of Amendment of Amended and Restated Certificate of Incorporation.   8-K   3.1   March 8, 2024
                   
    4.3 Third Amended and Restated Bylaws.   8-K   3.2   July 17, 2019
                   
    5.1* Opinion of Dentons US LLP.             
                   
    23.1* Consent of Baker Tilly US, LLP.            
                   
    23.2* Consent of Dentons US LLP (included in Exhibit 5.1).             
                   
    24.1* Power of Attorney (contained on signature page hereto).             
                   
    107* Filing Fee Table.            
                   
    99.1* 2026 Inducement Plan            

     

    * Filed herewith.

     

    5 

     

      

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on this 9th day of April 2026.

     

      IMMUNIC, INC.
      (Registrant)
         
      By: /s/ Daniel Vitt
        Name: Daniel Vitt
        Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Daniel Vitt and Glenn Whaley, and each of them, as his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign this Registration Statement on Form S-8 of Immunic, Inc., and any or all amendments thereto (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ DANIEL VITT   Chief Executive Officer (principal executive officer), Director   April 9, 2026
    Daniel Vitt        
             
    /s/ GLENN WHALEY   Chief Financial Officer (principal financial officer and principal accounting officer)   April 9, 2026
    Glenn Whaley        
             
    /s/ SIMONA SKERJANEC   Chair of the Board of Directors   April 9, 2026
    Simona Skerjanec        
             
    /s/ DUANE D. NASH   Director   April 9, 2026
    Duane D. Nash        
             
    /s/ TAMAR HOWSON   Director   April 9, 2026
    Tamar Howson        
             
    /s/ JOERG NEERMANN   Director   April 9, 2026
    Joerg Neermann        
             
    /s/ RICHARD RUDICK   Director   April 9, 2026
    Richard Rudick        
             
    /s/ BARCLAY A. PHILLIPS   Director   April 9, 2026
    Barclay A. Phillips        
             
    /s/ THORVALD NAGEL   Director   April 9, 2026
    Thorvald Nagel        
             
    /s/ JON CONGLETON   Director   April 9, 2026
    Jon Congleton        

     

    6

     

    Get the next $IMUX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMUX

    DatePrice TargetRatingAnalyst
    3/24/2026$7.00Buy
    Guggenheim
    11/7/2025$3.00Buy
    Roth Capital
    9/29/2025$13.00Buy
    Chardan Capital Markets
    3/25/2025Outperform
    William Blair
    11/25/2024$10.00Buy
    H.C. Wainwright
    9/9/2024$5.00Outperform
    Leerink Partners
    8/27/2024$6.00Buy
    B. Riley Securities
    10/21/2022$5.00Outperform → Mkt Perform
    SVB Leerink
    More analyst ratings

    $IMUX
    SEC Filings

    View All

    SEC Form S-8 filed by Immunic Inc.

    S-8 - IMMUNIC, INC. (0001280776) (Filer)

    4/9/26 4:30:55 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Immunic Inc.

    S-3 - IMMUNIC, INC. (0001280776) (Filer)

    4/2/26 4:31:29 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - IMMUNIC, INC. (0001280776) (Filer)

    4/1/26 7:00:32 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immunic to Participate in Scientific and Medical Conferences in April

    NEW YORK, April 9, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following scientific and medical conferences in April:April 14-16: 8th Annual Neuroimmunology Drug Development Summit. Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will give a presentation highlighting lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), at this conference in Boston. The presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.

    4/9/26 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

    NEW YORK, April 1, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on March 27, 2026, informing the company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.According to the Notice, Immunic has regained compliance with the minimum bid price requirement, because the closing bid price of the Company's common stock was at $1.00 pe

    4/1/26 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

    – Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis –– Served on Original Team Responsible for the Launch of Copaxone® in the United States –NEW YORK, March 31, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jon Congleton, a seasoned biopharmaceutical executive with nearly 40 years of experience spanning drug development, commercialization and corporate leadership, to its Board of Directors, effective March 27, 2026.Mr. Congleton has a strong track record of building and leadin

    3/31/26 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $IMUX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $IMUX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Congleton Jon

    3 - IMMUNIC, INC. (0001280776) (Issuer)

    3/31/26 4:01:12 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Bvf Partners L P/Il claimed ownership of 7,590,690 shares (SEC Form 3)

    3 - IMMUNIC, INC. (0001280776) (Issuer)

    2/27/26 5:03:09 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Nagel Robert Thorvald

    3 - IMMUNIC, INC. (0001280776) (Issuer)

    2/27/26 5:00:26 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Immunic with a new price target

    Guggenheim initiated coverage of Immunic with a rating of Buy and set a new price target of $7.00

    3/24/26 8:40:25 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Immunic with a new price target

    Roth Capital initiated coverage of Immunic with a rating of Buy and set a new price target of $3.00

    11/7/25 8:30:20 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Immunic with a new price target

    Chardan Capital Markets initiated coverage of Immunic with a rating of Buy and set a new price target of $13.00

    9/29/25 9:57:47 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President and COO Tardio Jason bought $9,884 worth of shares (12,512 units at $0.79) (SEC Form 4)

    4/A - IMMUNIC, INC. (0001280776) (Issuer)

    6/20/25 5:16:19 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: CEO and Director Vitt Daniel bought $11,550 worth of shares (15,000 units at $0.77), increasing direct ownership by 107% to 29,000 units (SEC Form 4)

    4/A - IMMUNIC, INC. (0001280776) (Issuer)

    6/20/25 5:15:45 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman Nash Duane bought $16,694 worth of shares (20,000 units at $0.83), increasing direct ownership by 125% to 36,032 units (SEC Form 4)

    4 - IMMUNIC, INC. (0001280776) (Issuer)

    6/16/25 5:00:19 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immunic Inc.

    SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

    11/14/24 5:33:45 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immunic Inc.

    SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

    11/14/24 12:30:35 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immunic Inc.

    SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

    11/14/24 6:58:13 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Leadership Updates

    Live Leadership Updates

    View All

    Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

    – Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis –– Served on Original Team Responsible for the Launch of Copaxone® in the United States –NEW YORK, March 31, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jon Congleton, a seasoned biopharmaceutical executive with nearly 40 years of experience spanning drug development, commercialization and corporate leadership, to its Board of Directors, effective March 27, 2026.Mr. Congleton has a strong track record of building and leadin

    3/31/26 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Highlights 2024 Accomplishments and Upcoming Milestones

    – Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 – – Strengthened Management Team and Board of Directors with Key Hires – – Announced a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered,

    1/7/25 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

    – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK, July 24, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Simona Skerjanec, M.Pharm, MBA, a thought-leader in brain health with decades of experience in drug development and commercialization, to its board of directors, effective July 22, 2024. Over a nea

    7/24/24 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Financials

    Live finance-specific insights

    View All

    Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

    – 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes – – NfL Effect in Non-Active Subpopulation Reinforces Vidofludimus Calcium's Neuroprotective Potential – – Brain Volume Data of the Full 467 CALLIPER Patient Cohort Expected in April 2025 – – Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing – – Conference Call and Webcast to be Held Tomorrow, October 10, 2023 at 8:00 am ET – NEW YORK, Oct. 9, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chr

    10/9/23 4:01:00 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

    – Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of Patients' Symptoms, Biomarker Response, and Enhancement of Nutrient Absorption – – Corroborates Hypothesized Ability of IMU-856 to Renew Gut Wall and Restore Gut Health – – No Safety or Tolerability Issues Detected – – Conference Call and Webcast to be Held Today, May 4, 2023 at 8:00 am ET – NEW YORK, May 4, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive results fro

    5/4/23 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

    – 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of Vidofludimus Calcium Demonstrated Statistically Significant Rates of Clinical Remission (p=0.0358) and Endoscopic Healing (p=0.0259) at Week 50 – – To Focus Resources on High Performing Vidofludimus Calcium and IMU-856 Programs, Immunic Decided to Deprioritize Izumerogant (IMU-935) Program – – Conference Call and Webcast to be Held today, April 5, 2023 at 8:00 am ET – NEW YORK, April 5, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi

    4/5/23 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care